Literature DB >> 17448989

Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.

Jan Münch1, Ludger Ständker, Knut Adermann, Axel Schulz, Michael Schindler, Raghavan Chinnadurai, Stefan Pöhlmann, Chawaree Chaipan, Thorsten Biet, Thomas Peters, Bernd Meyer, Dennis Wilhelm, Hong Lu, Weiguo Jing, Shibo Jiang, Wolf-Georg Forssmann, Frank Kirchhoff.   

Abstract

A variety of molecules in human blood have been implicated in the inhibition of HIV-1. However, it remained elusive which circulating natural compounds are most effective in controlling viral replication in vivo. To identify natural HIV-1 inhibitors we screened a comprehensive peptide library generated from human hemofiltrate. The most potent fraction contained a 20-residue peptide, designated VIRUS-INHIBITORY PEPTIDE (VIRIP), corresponding to the C-proximal region of alpha1-antitrypsin, the most abundant circulating serine protease inhibitor. We found that VIRIP inhibits a wide variety of HIV-1 strains including those resistant to current antiretroviral drugs. Further analysis demonstrated that VIRIP blocks HIV-1 entry by interacting with the gp41 fusion peptide and showed that a few amino acid changes increase its antiretroviral potency by two orders of magnitude. Thus, as a highly specific natural inhibitor of the HIV-1 gp41 fusion peptide, VIRIP may lead to the development of another class of antiretroviral drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17448989     DOI: 10.1016/j.cell.2007.02.042

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  87 in total

Review 1.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

2.  Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses.

Authors:  Mireille R St Vincent; Che C Colpitts; Alexey V Ustinov; Muhammad Muqadas; Michael A Joyce; Nicola L Barsby; Raquel F Epand; Richard M Epand; Stanislav A Khramyshev; Olga A Valueva; Vladimir A Korshun; D Lorne J Tyrrell; Luis M Schang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-07       Impact factor: 11.205

Review 3.  Novel targets for antiretroviral therapy: clinical progress to date.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Drugs       Date:  2009       Impact factor: 9.546

4.  Identification of the LWYIK motif located in the human immunodeficiency virus type 1 transmembrane gp41 protein as a distinct determinant for viral infection.

Authors:  Steve S-L Chen; Polung Yang; Po-Yuan Ke; Hsiao-Fen Li; Woan-Eng Chan; Ding-Kwo Chang; Chin-Kai Chuang; Yu Tsai; Shu-Chen Huang
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

Review 5.  Molecular targets for flavivirus drug discovery.

Authors:  Aruna Sampath; R Padmanabhan
Journal:  Antiviral Res       Date:  2008-09-15       Impact factor: 5.970

Review 6.  Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.

Authors:  Judith M White; Sue E Delos; Matthew Brecher; Kathryn Schornberg
Journal:  Crit Rev Biochem Mol Biol       Date:  2008 May-Jun       Impact factor: 8.250

Review 7.  Development of topical microbicides to prevent the sexual transmission of HIV.

Authors:  Robert W Buckheit; Karen M Watson; Kathleen M Morrow; Anthony S Ham
Journal:  Antiviral Res       Date:  2009-10-27       Impact factor: 5.970

Review 8.  HIV infection of the genital mucosa in women.

Authors:  Florian Hladik; Thomas J Hope
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

9.  Internal dynamics of the homotrimeric HIV-1 viral coat protein gp41 on multiple time scales.

Authors:  Nils-Alexander Lakomek; Joshua D Kaufman; Stephen J Stahl; John M Louis; Alexander Grishaev; Paul T Wingfield; Ad Bax
Journal:  Angew Chem Int Ed Engl       Date:  2013-02-28       Impact factor: 15.336

10.  A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.

Authors:  Guofeng Cheng; Ana Montero; Pablo Gastaminza; Christina Whitten-Bauer; Stefan F Wieland; Masanori Isogawa; Brenda Fredericksen; Suganya Selvarajah; Philippe A Gallay; M Reza Ghadiri; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.